Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Guigay

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
European Annals of Otorhinolaryngology, Head and Neck Diseases|July 4, 2015
Guidelines (short version) of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making processS Deneuve, E Babin, J Lacau-St-Guily, et al.
Revue Des Maladies Respiratoires|May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialP M Clement, T Gauler, J P Machiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trialY Tao, J Biau, X S Sun, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
World Journal of Surgery|August 9, 2017
Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort StudyP Lecomte, C Binquet, M Le Bras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
European Annals of Otorhinolaryngology, Head and Neck Diseases|July 4, 2015
Guidelines (short version) of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making processS Deneuve, E Babin, J Lacau-St-Guily, et al.
Revue Des Maladies Respiratoires|May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialP M Clement, T Gauler, J P Machiels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trialY Tao, J Biau, X S Sun, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
World Journal of Surgery|August 9, 2017
Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort StudyP Lecomte, C Binquet, M Le Bras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Pageof 7